The abstract is read at the publisher; the summary is JClub's.
First-line sunvozertinib improves progression-free survival versus carboplatin-pemetrexed in advanced nonsquamous NSCLC with EGFR exon 20 insertions, reaching 10.3 vs 7.5 months.
- Why it matters: Although sunvozertinib is approved for later-line advanced NSCLC with EGFR exon 20 insertions, its first-line efficacy and safety were uncertain.
- What they did: In a phase 3 international trial, 324 patients were randomized 1:1 to sunvozertinib or carboplatin-pemetrexed, with progression-free survival assessed by blinded independent central review.
- The result: Sunvozertinib produced higher objective response rates (58.9% vs 31.1%) and longer median duration of response (11.2 vs 7.1 months), but also more grade 3+ adverse events (75.5% vs 56.7%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.